Acquired resistance in cancer: towards targeted therapeutic strategies. Read more about Acquired resistance in cancer: towards targeted therapeutic strategies.
Revisiting the TGFβ paradox: insights from HPV-driven cancer and the DNA damage response. Read more about Revisiting the TGFβ paradox: insights from HPV-driven cancer and the DNA damage response.
Defining precancer: a grand challenge for the cancer community. Read more about Defining precancer: a grand challenge for the cancer community.
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart. Read more about Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart.
Next-generation epidemiologic cohorts for cancer aetiology. Read more about Next-generation epidemiologic cohorts for cancer aetiology.
Defining and using immune archetypes to classify and treat cancer. Read more about Defining and using immune archetypes to classify and treat cancer.
Rethinking cancer targeting strategies in the era of smart cell therapeutics. Read more about Rethinking cancer targeting strategies in the era of smart cell therapeutics.
Expanding oesophageal cancer research and care in eastern Africa. Read more about Expanding oesophageal cancer research and care in eastern Africa.
